All Life

In 2015, the United Nations adopted the 2030 Agenda for Sustainable Development, which is comprised of 17 Sustainable Development Goals (SDGs). SDG 3 targets good health and well-being, with the goal of improving global health outcomes. There has been notable progress in achieving this goal with several important health strides addressing SDG3. This includes an ever-expanding drug discovery pipeline and background translational research to gather drug toxicology and efficacy data prior to clinical trial initiation.

Though focus has been brought to translational research and the drug discovery pipeline, there are still many challenges that face researchers.  This includes, but is not limited to, increasing cost and decreasing funding, limitations in research models that may not recapitulate human phenotype, and limited mechanistic understanding of how a particular drug may work. Even now, only 10% of drugs in the discovery pipeline make it through clinical trials to approval.

In this Article Collection, All Life addresses SDG3: Good Health and Well-Being through innovative open scientific research addressing genetic diseases or new methods of personalized medicine under the sections “Pharmacology & Pharmaceutics”, and “Translational Physiology”. This Article Collection will accept original research articles, reviews, short communications, data notes, and commentaries on topics including, but not limited to:

1. Drug discovery pipeline
2. Drug validation in preclinical models of diseases
3. Side effects and unexpected effects of drugs
4. Drugs repositioning for other diseases
5. Drug pharmacokinetic and metabolization studies
6. Toxicology reports from pre-clinical and clinical trials
7. Repurposing orphan drugs
8. Limitations of the drug discovery pipeline

---

The deadline for submitting manuscripts is 30 April 2025.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Please be sure to select the appropriate Article Collection from the drop-down menu in the submission system, and please select “Pharmacology & Pharmaceutics”, and “Translational Physiology” from the list of available sections during submission. Failure to select the appropriate Article Collection or Section name can result in delays.

---

Prof. Dr. Amar ABDERRAHMANI is Full Professor of Cell and Molecular Biology at the Faculty of Medicine at Lille University. He is currently the head of the team devoted to nanomaterials for health in the institute of electronics, microelectronics, and nanotechnologies. He has a multidisciplinary background including a PhD and pharmacy graduation in Molecular genetics and pharmaceutical chemistry. AA has been honoured by several Swiss awards and in 2011, of National Chair of Excellence in beta-cell biology, bioscience and diabetes. AA has been member of several scientific committees of Diabetes Association.

Instructions for AuthorsSubmit an Article